Enlivex Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
The Fundamentalytics view
Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 31648% in the quarter to 2026-06-30, the 2nd beat in the last four quarters.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Enlivex Ltd.'s latest figures clears our strength thresholds.
Things to watch
- Share dilution. Diluted shares rose 136.4% in a year.
- Weak cash conversion. Free cash flow was -1% of net income over the last 12 months.
Latest results
- Earnings per share
- $1564.80 against an average estimate of -$4.96: beat by 31648.4%
Price chart
- 1 day+2.1%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- EPS (TTM, diluted)
- $25.48
Growth
- Share count change
- +136.4%
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for ENLV from the sources we follow. See filings →
No model value for Enlivex Ltd. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
Valuation models
We value Enlivex Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | ~$48 ~$38–$110 | Left out: out of range vs price (34.18x) |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | ~$14 ~$9.6–$21 | Left out: out of range vs price (9.90x) |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | ~$13 ~$12–$16 | Left out: out of range vs price (9.41x) |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Enlivex Ltd. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$18.40 | −100% | — | 0% |
| Next | −$3.36 | +82% | — | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −4.2% on 90 days ago. In the last 30 days, 1 analyst raised Enlivex Ltd.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$19.20 | −$21.60 |
| 60 days ago | −$19.20 | −$21.60 |
| 30 days ago | −$19.20 | −$21.60 |
| 7 days ago | −$19.20 | −$21.60 |
| Now | −$18.40 | −$3.36 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$4.96 | $1564.80 | +31648.4% |
| Dec 2025 | −$7.20 | −$22.51 | −212.7% |
| Sept 2025 | −$28.80 | −$21.60 | +25.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 0.8% of tradable shares
- Days to cover
- 0.07 at average volume
- Short interest, 1 month
- +231% to October 15, 2026
- Held by institutions
- 1% of shares
- Held by insiders
- 55.9% of shares
- Employees
- 34 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Dividends, buybacks and capital spending
- Diluted share count
- +136.4%
- year over year
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Recent SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Enlivex Ltd. in brief
- What does Enlivex Ltd. do?
- Enlivex Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Enlivex Ltd.'s stock ticker?
- Enlivex Ltd. trades under the ticker ENLV on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Follow research on Enlivex Ltd.
New research on the companies we cover arrives in the weekly email. Free, one email a week.